echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 50 new domestic funded projects, such as biomedicine, settled in Binhai New Area, Tianjin

    50 new domestic funded projects, such as biomedicine, settled in Binhai New Area, Tianjin

    • Last Update: 2019-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network industry trends] according to new statistics from Binhai New Area, in the first half of 2019, 2115 domestic funded projects were settled in the area, with an investment of 141.5 billion yuan Among the settled domestic funded projects, the number of strategic emerging industries increased significantly compared with the same period last year, including 50 domestic funded intelligent manufacturing, biomedicine, new energy and new material projects, up 400% year on year In terms of biomedical industry, the increase of domestic funded projects can not be separated from Tianjin's policy support for the industry It is reported that on June 27 this year, Tianjin issued "several opinions on further supporting the high-quality development of biomedical industry in Tianjin", and launched 10 types of support policies, aiming to speed up the high-quality development of biomedical industry
    These 10 types of supporting policies include: comprehensively integrating and simplifying the review and approval procedures, elements and processes, attracting innovative, leading and complementary medical device manufacturers to settle in Tianjin; vigorously supporting innovative drug manufacturers to implement production; accelerating the quality and efficacy consistency evaluation of generic drugs; accelerating the implementation of the pilot system for drug listing license holders; encouraging biomedical Enterprises Improve the comprehensive ability of the industry In addition, in order to promote the high-quality development of Tianjin biomedical industry and improve the scientific level of decision-making, Tianjin biomedical industry expert advisory committee was established at the beginning of this year It is reported that there are 21 expert members in Tianjin biomedical industry expert advisory committee, including 10 academicians of the two academies, 5 experts of scientific research institutes and 6 entrepreneurs, and 9 experts from other provinces and cities The establishment of the committee will give full play to the professional advantages and academic achievements of experts, and contribute to the realization of high-quality development of Tianjin biomedical industry For a long time, Tianjin Binhai New Area has achieved remarkable results in industrial restructuring, and emerging industries have continued to grow By the end of July this year, Tianjin Binhai New Area has 2206 national high-tech enterprises, accounting for more than 40% of the city's total; 1853 National Science and technology SMEs, 33000 Municipal Science and technology SMEs, 104 new third board listed enterprises; 478 municipal R & D platforms, including 64 According to the industry, Tianjin Binhai New Area is focusing on strategic emerging industries such as artificial intelligence, biomedicine, new energy and new materials and equipment, striving to capture a number of "neck sticking" technologies in new vaccines and other fields, forming a number of "killer" products The data shows that the biomedical industry in Tianjin has maintained a rapid growth trend in recent years In 2018, the industrial added value of Tianjin was 696.271 billion yuan, up 2.6% year on year; the pharmaceutical manufacturing industry increased 8.8%, 6% higher than the industrial added value According to the three year action plan for the development of Tianjin biomedical industry (2018-2020), by 2020, the scale of Tianjin biomedical industry will reach about 150 billion yuan, striving to build into an important national innovation base for biomedical industry and a global influential R & D and transformation base for biomedical industry As we all know, the R & D cycle of new drugs is long and the risk is large A new drug usually takes 8-12 years from R & D to market, and the rate is not high The use of artificial intelligence in new drug research and development is conducive to solving these problems In the development upsurge of the continuous integration of artificial intelligence and biomedicine, Tianjin Binhai New Area is also actively investing in this field For example, as early as 2018, Tianjin International Biomedical Joint Research Institute signed a strategic cooperation agreement with Beijing Tianyun big data to further promote the integration of artificial intelligence and biomedical industry.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.